Please ensure Javascript is enabled for purposes of website accessibility

1 Key Thing You Might Be Overlooking With Inovio

By Keith Speights – Aug 27, 2020 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's coronavirus vaccine candidate gets the spotlight, but you might want to shine some light on this program, too.

You can't read an article about Inovio Pharmaceuticals (INO 2.62%) without its coronavirus vaccine candidate INO-4800 receiving prominent attention. This article is obviously no exception.

It makes sense why INO-4800 is the primary focus of investors. If the vaccine is successful in phase 2 clinical testing and goes on to eventually win regulatory approval, Inovio will become a much bigger company in a hurry.

But there's one key thing that you might be overlooking with Inovio that could potentially be a game-changer for the biotech.

Ascending stacks of blocks with a gap between the last two stacks, a chess pawn with a question mark over it on top of the next-to-last stack, and a DNA image over the last stack.

Image source: Getty Images.

In the lead

Based on the extensive coverage of INO-4800, you'd think that the vaccine candidate is Inovio's lead pipeline candidate. But it isn't. That distinction goes to VGX-3100.

Until earlier this year, any discussion of Inovio would have almost certainly centered on VGX-3100. Inovio is currently evaluating the immunotherapy in two phase 3 clinical studies as a potential treatment for human papillomavirus (HPV)-related precancerous cervical dysplasia, also known as high-grade squamous intraepithelial lesions (HSIL).

The company expects to report top-line results from the first of these two late-stage studies in the fourth quarter of this year. Patient enrollment for the second study continues across 43 recruiting sites. The study should wrap up in the first half of 2021. 

Inovio reported encouraging interim results in March from a couple of phase 2 studies evaluating VGX-3100. One of these studies showed promise for the experimental drug in treating HPV-related anal dysplasia. The other study demonstrated positive results from using VGX-3100 in treating women with vulvar dysplasia.  

A big opportunity

Sure, INO-4800 could potentially be used to vaccinate hundreds of millions and even billions of people if it's successful. However, it would almost certainly have to compete against other COVID-19 vaccines. There are at least nine candidates ahead of INO-4800 in clinical testing. 

But VGX-3100 wouldn't have such a problem. There currently aren't any drugs approved by the Food and Drug Administration for treating cervical dysplasia. The only treatment option is invasive surgery.

It's a similar story for anal dysplasia, with current treatments limited to surgical excision, electro-cauterization, or laser therapy. Those alternatives aren't attractive, especially considering that up to half of patients experience a recurrence of anal dysplasia within one year of treatment, with almost 70% experiencing recurrence within three years of treatment.

And there's a substantial market for VGX-3100 if it's approved in the targeted indications. That's especially true for cervical dysplasia, as around 195,000 people in the U.S. and 233,000 people in Europe are diagnosed with the disease each year. Market researcher EvaluatePharma projects that VGX-3100 could generate peak annual sales of more than $600 million if approved.

Risks

Inovio's market cap currently stands at a little over $2 billion. If VGX-3100 goes on to win approval and meet commercial expectations, the biotech stock could come close to doubling based on the prospects for the one immunotherapy alone. And that doesn't factor in the potential of Inovio's other pipeline candidates that have nothing to do with the coronavirus.

There remains uncertainty about how VGX-3100 will fare in late-stage testing, though. Over 35% of therapies targeting infectious diseases that made it to phase 3 clinical studies didn't win FDA approval between 2006 and 2015, according to an analysis by Biotechnology Innovation Organization, an industry trade group. Two-thirds of oncology-related candidates in phase 3 testing failed to secure FDA approval during the period.

VGX-3100 is an immunotherapy that targets precancerous conditions caused by a virus. It's probably safe to assume that the drug's chances of obtaining FDA approval aren't better than 65% or so, using history as a guide. 

Inovio doesn't have a slam dunk with any of its pipeline candidates, but its prospects should improve when you look at all of its shots on goal. INO-4800 gets most of the spotlight these days for the biotech, but VGX-3100 merits attention, too.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.76 (2.62%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.